Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.89 |
| ▸ | NPC1 | O15118 | 9/20 | 0.86 |
| ▸ | RAB9A | P51151 | 9/20 | 0.86 |
| ▸ | LMNA | P02545 | 3/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.64 |
| ▸ | RELA | Q04206 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17115776 | 0.93 | NPC1 (1.00) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL14825062 | 0.93 | NPC1 (1.00) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL27471728 | 0.91 | MEN1 (0.74) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL6814456 | 0.90 | MEN1 (0.77) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL30739608 | 0.89 | LMNA (1.00) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL6295702 | 0.89 | LMNA (1.00) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL4102438 | 0.88 | MEN1 (0.80) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL30739691 | 0.87 | KMT2A (0.68) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL11359908 | 0.85 | NPC1 (0.66) | MEN1KMT2ATDP1NPC1RAB9A | |
| SCHEMBL679040 | 0.85 | MEN1 (0.83) | MEN1KMT2ATDP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118044519-A | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-110072842-B | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-2365809-B1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMA INC (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| CN-106146411-A | (S) preparation method of-2-(1-amino-propyl)-5-fluoro-3-phenyl-3H-quinazoline-4-one | 上海医药工业研究院 | 2016-11-23 | — | — | CN | disclosed |
| CN-106146352-A | Idelalisib intermediate and preparation method thereof | 上海医药工业研究院 | 2016-11-23 | — | — | CN | disclosed |
| CN-105431437-A | PI3K protein kinase inhibitors, in particular inhibitors and/or gamma inhibitors | RHIZEN PHARMACEUTICALS SA | 2016-03-23 | — | — | CN | disclosed |
| CN-104513235-A | Substituted aminopyrimidine compound and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-04-15 | — | — | CN | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| WO-2010068292-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-7589089-B2 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-2021331-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-02-11 | — | — | EP | disclosed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058331-A1 | Inhibitors for GlyT-1 | GLRA1, SLC1A2, AGXT | MEN1 2246/4885KMT2A 218/4885TDP1 816/4885 |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | MEN1 3066/4885KMT2A 2104/4885TDP1 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.